Spyre Therapeutics, Inc. SYRE Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -25.2%+34.1pp | -59.3%+230pp | -289.2%-164pp | -124.9%-66.1pp | |
| Efficiency | |||||
| Asset turnover | 0×— | 0×0.0× | 0×0.0× | 0×-0.1× | |
| Liquidity | |||||
| Current ratio | 13.3×+2.0× | 11.3×+0.6× | 10.7×+6.4× | 4.2×-0.7× | |
| Per Share | |||||
| Book value per share | $11.17+1.4% | $11.01-58.7% | $26.68+78.8% | $14.92-53.3% | |
| Valuation | |||||
| Market capitalization | $2.54B+82.6% | $1.39B+79.6% | $775.17M+2,536% | $29.41M-90.6% | |
| Price / book | 3.6×+0.9× | 2.7×-1.5× | 4.2×+3.6× | 0.6×-3.1× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Spyre Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Spyre Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.